MORGAN STANLEY PLC/CALL/BECTON DICKINSON AND CO./300/0.1/20.09.24 Stock

Warrant

DE000MG03821

Real-time Bid/Ask 10:45:07 2024-05-21 EDT
0.073 EUR / 0.104 EUR +18.67% Intraday chart for MORGAN STANLEY PLC/CALL/BECTON DICKINSON AND CO./300/0.1/20.09.24
Current month-41.86%
1 month-36.97%
Date Price Change
24-05-21 0.061 -18.67%
24-05-20 0.075 0.00%
24-05-17 0.075 -3.85%
24-05-16 0.078 -3.70%
24-05-15 0.081 +2.53%

Delayed Quote Börse Stuttgart

Last update May 21, 2024 at 02:11 am

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying BECTON, DICKINSON AND COMPANY
Issuer Morgan Stanley
WKN MG0382
ISINDE000MG03821
Date issued 2024-03-12
Strike 300 $
Maturity 2024-09-20 (122 Days)
Parity 10 : 1
Emission price 0.15
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 0.205
Lowest since issue 0.061
Spread 0.031
Spread %29.81%

Company Profile

Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows: - medical equipment (73.5%): surgical instruments, urological care products, pharmaceutical systems, etc.; - diagnostic materials (18.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, etc.; - clinical research and development tools (7.8%): tools for discovering drugs and vaccines, studying genes, culturing cells, and manipulating liquids, instruments for sorting and analyzing cells, monoclonal antibodies, etc. Net sales are distributed geographically as follows: the United States (57.4%), Europe/Middle East/Africa (21.9%), Asia (15%) and other (5.7%).
Sector
-
More about the company

Ratings for Becton, Dickinson and Company

Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings

Consensus: Becton, Dickinson and Company

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
237.1 USD
Average target price
279 USD
Spread / Average Target
+17.66%
Consensus
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW